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The cytochrome P450 CYP1B1 is consistently overexpressed in tumour cells as compared to their normal counterparts, but its
precise role in drug resistance is yet to be defined. It has been reported that transfection of CYP1B1 results in increased resistance to
docetaxel in V79 cells (McFadyen et al, 2001). In this study, we analysed changes in expression of CYP1B1 mRNA associated with
pulse selection of MCF-7 cells with docetaxel. Docetaxel-selected MCF-7 cells (MCF-7 Txt), which showed increased resistance to
this drug as compared to parental MCF-7 cells, showed a noteworthy increase in CYP1B1 mRNA expression, paralleled by increased
ethoxyresorufin-O-deethylase (EROD) activity levels. This effect was not observed in cisplatin- or adriamycin-selected MCF-7 cells, or
in docetaxel-selected colon, lung or pancreatic carcinoma cells. Short-term treatment with docetaxel induced CYP1B1 mRNA
expression in MDA 453 and BT-20 breast carcinoma cells, but not in MCF-7 cells. Transfection of MCF-7 Txt cells with CYP1B1
siRNA did not significantly affect docetaxel-induced toxicity, but it decreased cell survival in the absence of drug. Preincubation of
docetaxel with recombinant CYP1B1 did not affect drug toxicity in A549 cells. These results suggest that CYP1B1 does not directly
inactivate docetaxel, but rather might promote cell survival in MCF-7 Txt cells, providing an explanation for its association with drug
resistance.
British Journal of Cancer (2008) 98, 564–570. doi:10.1038/sj.bjc.6604195 www.bjcancer.com
Published online 22 January 2008
& 2008 Cancer Research UK
Keywords: cytochromes P450; CYP1B1; drug resistance; breast
                                             
Breast cancer affects a significant number of women worldwide and
is a leading cause of cancer deaths (Chintamani et al,2 0 0 4 ) .C u r r e n t
therapies for breast cancer include locoregional (surgical) treatment,
anti-hormone therapy, radiotherapy and chemotherapy (O’Driscoll
and Clynes, 2006). Chemotherapeutic treatment of breast cancer,
although of great importance in the management of the disease, has
limited benefits for many patients due to intrinsic or acquired
resistance to the effects of anticancer drugs. Moreover, chemoresis-
tance is often associated with a more aggressive phenotype with an
increased tendency to invade and metastasise (Campbell et al, 2001).
Cytochromes P450 are a family of enzymes implicated in the
biotransformation of both xenobiotics and endogenous com-
pounds. Their primary functions are the synthesis of steroids and
bile acids and the detoxification of many foreign substances, such
as drugs and environmental agents.
CYP1B1 is the only member of the CYP1B subfamily; it catalyses
the hydroxylation of 17-b-oestradiol at the C4 position (Jefcoate
et al, 2000) and is involved in testosterone biotransformation as
well (Shimada et al, 1999). It is also known to metabolise
xenobiotics such as ethoxyresorufin, theophylline and caffeine
(Shimada et al, 1997). CYP1B1 is constitutively expressed at the
mRNA level in mammal steroidogenic tissues, such as rat
granulosa cells (Dasmahapatra et al, 2002) and its expression
can be induced in these and other tissues by peptide hormones,
cAMP and ligands of the aryl hydrocarbon receptor (AhR). Cross-
talk has been described between the oestrogen receptor (ER)a and
the CYP1B1 expression pathways (Spink et al, 1998). Regulation of
expression appears to be tissue-specific, since treatment with the
AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces
CYP1B1 mRNA in MCF-7 cells but not in HepG2 cells (Spink et al,
1994). More recently, regulation of CYP1B1 expression by
microRNAs has been described (Tsuchiya et al, 2006).
Conflicting data exist in the literature regarding CYP1B1
expression. A number of studies failed to detect presence or activity
of functional CYP1B1 protein in normal (nontumour) tissue (Murray
et al, 1997; McFadyen et al, 1999); however, expression of CYP1B1 in
normal tissue has been reported, although in much lower levels than
in tumour tissue, at both mRNA and protein levels (Muskhelishvili
et al, 2001; Gibson et al, 2003). In spite of these inconsistencies, most
studies agree that CYP1B1 protein is commonly overexpressed in
malignant as compared to normal tissue.
The significance of CYP1B1 overexpression in cancer is not yet
fully understood, but the fact that it can inactivate flutamide, an
antiandrogen used in the treatment of prostate cancer, with high
efficiency suggests that this enzyme might play an important role in
the development of resistance to some forms of chemotherapy
(Rochat et al, 2001). Also, a significant decrease in the sensitivity of
CYP1B1-transfected V79 Chinese hamster ovary cells to docetaxel as
compared to the parental cell line has been described (McFadyen
et al, 2001); cytotoxicity was restored by pretreating the cells with the
CYP1 inhibitor a-naphtoflavone. Although transfection of CYP1B1
has been reported to confer resistance to docetaxel, no metabolites
could be detected after incubation of this drug with recombinant
CYP1B1 in a number of different conditions (Bournique and Lemarie,
2002). Thus, even though expression of CYP1B1 appears to be
associated with drug resistance, its precise role remains obscure.
In this study, we report induction of CYP1B1 mRNA expression
by docetaxel in breast cell lines, both after short-term treatment
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sand pulse-selection. The docetaxel-mediated increase in CYP1B1
expression was cell type-specific, as lung, pancreas and colon cell
lines pulse-selected with docetaxel did not show such induction.
CYP1B1 small interfering RNA (siRNA) transfection resulted in
decreased cell survival, but did not cause major changes in
docetaxel toxicity. Overall, expression of CYP1B1 appears to
promote cell survival in MCF-7 Txt cells; this effect might
significantly contribute to the increase in drug resistance observed
in these cells.
MATERIALS AND METHODS
Chemicals
Cell culture media were obtained from Gibco BRL (Paisley, UK);
serum was from Sigma (Poole, UK). Docetaxel was obtained from
Sanofi Aventis Pharmaceuticals (Surrey, UK), cisplatin was
from Mayne Pharma Plc. (Warwickshire, UK) and paclitaxel
was from Bristol-Myers Squibb (Dublin, Ireland). 5-fluorouracil
was obtained from Faulding Pharmaceuticals (Warwickshire, UK)
and adriamycin was from Ebewe (Unterach, Austria). Reverse
transcription polymerase chain reaction (RT–PCR) reagents and
all other chemicals were purchased from Sigma.
Cell lines
MCF-7, BT-20, MDA 231 and MDA 453 breast carcinoma and
A549 lung adenocarcinoma cells were obtained from the ATCC
(American Type Culture Collection). BT-20 cells, MCF-7 cells and
their pulse-selected variants were maintained in MEM supple-
mented with 10% fetal calf serum (FCS), 1mM sodium pyruvate
and 1mM non-essential amino acids. MDA 231 and MDA 453 cells
were maintained in RPMI supplemented with 10% FCS. A549 cells
were maintained in a 1:1 mixture of DMEM and Ham’s F12
medium supplemented with 5% FCS. Cell lines were cultured in a
humidified atmosphere of 95% air/5% CO2. All docetaxel-selected
variants were referred to as Txt, for example, MCF-7 Txt;
adriamycin-selected variants were referred to as Adr and cisplatin
as CisPt.
Pulse selection of cells
MCF-7 cells were pulse-selected with adriamycin (4 pulses, once a
week for 4h, with 250ngml
 1 adriamycin), cisplatin (9 pulses,
once a week for 4h, with 800, 100, 300, 300, 300, 300, 300, 350,
350ngml
 1 cisplatin, respectively for each week) and docetaxel (6
pulses, once a week for 4h, except for the first one, which was for a
half hour, with 50, 10, 10, 13, 13, 13ngml
 1 docetaxel, respectively)
to generate the MCF-7 Adr, MCF-7 CisPt and MCF-7 Txt variants,
correspondingly. Drug concentrations and pulse schedule were
decided based on changes in cell morphology and resistance; a
dynamic pulse schedule was used here according to our previous
experience with this cell line.
In vitro toxicity testing
Cytotoxicity testing of drugs was measured by the acid phospha-
tase assay as previously described (Martin and Clynes, 1991).
Briefly, cells were seeded at 1 10
3 cells per well in a 96-well plate
and left to attach overnight in a 5% CO2 incubator at 371C. The
appropriate concentrations of drug were prepared freshly at 2 
their final concentration and added to the plate on the following
day. The assay was terminated after a further 7-day incubation.
The concentration of drug causing a 50% kill (IC50 of the drug) was
determined using CalcuSyn (Biosoft, Cambridge, UK). Fold
resistance was calculated as the ratio between IC50 values in
parent and pulse-selected cells. All assays were performed at least
in triplicate.
RT–PCR
Adherent cells were grown in 75cm
2 flasks until approximately
80% confluent; mRNA was then extracted using TRI reagent
(Sigma) according to the manufacturer’s instructions. RNA was
quantified spectrophotometrically at 260 and 280nm using the
Nanodrop (Nanodrop Technologies, Wilmington, DE, USA). One
microgram of mRNA was then subjected to reverse transcription
and the resulting cDNA amplified by PCR. The sequences of
primers used for CYP1B1 amplification were GTATATTGTTGAA
GAGACAG for the forward primer and AAAGAGGTACAACAT
CACCT for the reverse primer (Baron et al, 1998); b-actin was used
as control. The mixture was amplified for 35 cycles using the
following conditions: 941C for 3min, 491C for 30s, 721C for 1min.
Polymerase chain reaction products were then separated on a 2%
agarose gel and visualised by ethidium bromide staining on a UV
transilluminator.
Determination of EROD activity
Ethoxyresorufin-O-deethylase (EROD) activity of cells in culture
was determined as previously described (Bandiera et al, 2005).
Briefly, cells were incubated with a 400nM solution of
7-ethoxyresorufin in PBS pH 7.4 at 371C/5% CO2 for 60min. After
incubation, 200ml of the cell supernatant was transferred to an
opaque 96-well plate and fluorescence were determined at 530nm
excitation and 590nm emission in a fluorescence plate reader
(Synergy HT; Bio-Tek, Winooski, Vermont, USA). The sample
measurements were compared to a resorufin (Sigma; R3257)
standard curve. Ethoxyresorufin-O-deethylase activity was then
calculated as the measured amount of resorufin (in picomoles),
divided by the total protein content of the sample (in milligrams)
and by the total reaction time (in minutes).
RNA interference
RNA interference analysis was performed using siRNAs chemically
synthesised and purchased from Ambion Inc., Warrington, UK).
Three different siRNAs for CYP1B1 were used (Ambion Ids.
2253, 105952 and 112548). Small interfering RNAs were introduced
into the cells via reverse transfection with the transfecting
agent siPORTt NeoFXt (Ambion Inc.). Conditions for transfec-
tion were optimised using kinesin siRNA (Ambion Inc.). Solutions
of negative control (scrambled), kinesin and CYP1B1 siRNAs
at a final concentration of 30nM were prepared in optiMEM
(Gibcot). NeoFX solutions were also prepared in optiMEM
and incubated at room temperature for 10min. After incubation,
either scrambled, kinesin or CYP1B1 siRNA solution was added
to each NeoFX concentration; these solutions were mixed
thoroughly and incubated for a further 10min at room tempera-
ture. Replicates of 10ml of the siRNA/NeoFX solutions were added
to a 96-well plate. A total of 7.5 10
3 cells in 100ml were then
added to each well; the plates were mixed gently and incubated at
371C for 24h. After this period, the transfection mixture was
removed from the cells and the plates were fed with fresh medium.
Forty-eight hours after transfection, concentrations of the
chemotherapeutic agent (at 2  the final concentration) were
added to the plates in replicates of four. The plates were assayed
for changes in proliferation after a further 72h using the acid
phosphatase assay.
Drug metabolism by microsomes
Drug metabolism was investigated in the microsomal fraction of
recombinant insect cells (microsomes) expressing CYP1B1 and
cytochrome P450 NADPH reductase (P450R) (Beckton Dickinson,
Oxford, UK) or P450R alone. Fifty microlitres of a stock solution of
the appropriate drug were prewarmed at 371C in a total incubation
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smixture volume of 250ml containing potassium phosphate buffer
(PBS, pH 7.4), MgCl2 (25mM,2 5 ml) and NADPH (6.5mM,7 5 ml).
The reaction was initiated by the addition of 100mlofa1mgml
 1
solution of ice-cold microsomes to the incubation mixture, as
recommended by the manufacturer. After an incubation period of
either 30 or 60min, the mixture was filter sterilised and used for
toxicity assays as described above.
Statistical analysis
Differences between cell lines were assessed using a two-tailed
Student’s t-test. A P-value o0.05 was deemed significant.
RESULTS
Expression of CYP1B1 in MCF-7 cells and their
drug-resistant variants
CYP1B1 expression has been shown to be abundant in hormone-
dependent tissues such as uterus, ovary and breast (Tsuchiya et al,
2005). A breast cell line, MCF-7, was therefore chosen as a model in
which CYP1B1 expression might be studied.
MCF-7 cells were pulse-selected either with adriamycin, cisplatin
or docetaxel to generate the MCF-7 Adr, MCF-7 CisPt or MCF-7
Txt variants, respectively. Toxicity assays were carried out in these
cells to establish their resistance profile (Table 1). MCF-7 Adr were
4.8-fold more resistant to adriamycin than parent MCF-7 cells;
similarly, MCF-7 CisPt were 2.1-fold more resistant to cisplatin,
and MCF-7 Txt displayed a 2.8-fold increase in resistance against
docetaxel as compared to MCF-7 cells. Some cross-resistance
occurred in MCF-7 Adr and MCF-7 CisPt cells with docetaxel,
but it was not observed with other drugs or in any of the other cell
lines. Interestingly, MCF-7 Adr cells were more sensitive to
cisplatin than parental cells.
Expression of CYP1B1 mRNA was measured in MCF-7 cells and
their resistant variants by RT–PCR (Figure 1). The mRNA levels
of this enzyme were increased in MCF-7 Txt cells as compared to
parental cells. This upregulation of CYP1B1 expression was not
observed in MCF-7 Adr or MCF-7 CisPt cells; furthermore,
CYP1B1 mRNA levels appeared to be lower in these cells as
compared to parental MCF-7 cells. To confirm that the increase in
CYP1B1 transcription resulted in enhanced enzymatic activity,
EROD activity was measured in MCF-7 and their docetaxel-
selected variants. Activity was low but detectable in MCF-7 Txt
cells, while no measurable activity could be detected in MCF-7 cells
(Table 2).
Expression of CYP1B1 in a panel of docetaxel-selected cells
of various origins
To find out whether increased expression of CYP1B1 was a
common effect of docetaxel pulse selection, a panel of cell lines –
colon carcinoma Caco2, squamous cell lung carcinoma SK-MES-1
and pancreatic carcinoma BxPc-3 cell – and their docetaxel-
selected variants were analysed for CYP1B1 mRNA expression
(Figure 2). No CYP1B1 mRNA was detected in any of these cell
lines, whether pulse-selected or parent cells.
Effect of docetaxel on CYP1B1 expression in a panel of
breast cell lines
Upregulation of CYP1B1 mRNA expression in MCF-7 cells was
observed after long-term docetaxel treatment; however, it was not
clear whether docetaxel per se was able to induce CYP1B1 mRNA
expression or whether this effect was simply associated with the
development of resistance. To clarify this, the effect of a short-term
treatment with docetaxel on CYP1B1 mRNA expression was
analysed in a panel of breast cell lines: MCF-7, MDA 453, BT-20
and MDA 231. CYP1B1 is commonly expressed in hormone-
dependent tissue, such as prostate, breast and endometrium, and
its expression can be affected by the ER status of cells. We
therefore chose cell lines with different ER status: MCF-7 and MDA
453 cells are ER positive, while BT-20 and MDA 231 cells are ER
negative. These cells were exposed to 80ngml
 1 of docetaxel for
4h, and expression of CYP1B1 was then measured by RT–PCR
and compared to that of untreated cells. As can be seen in
Figure 3A, a single 4-h pulse of docetaxel did increase expression
of CYP1B1 mRNA in MDA 453 and BT-20 cells; a slight increase
was also observed for MDA 231 cells. No apparent effect on
expression was observed in MCF-7 cells after short-term docetaxel
treatment. These results suggest that induction of CYP1B1 mRNA
expression is not dependent on ER status.
To find out whether activation of the AhR can induce CYP1B1
expression in the panel of cell lines studied, cells were treated with
TCDD, a well-known AhR agonist, for 4h. Expression of CYP1B1
mRNA was then analysed and revealed upregulation of this
Table 1 5-Fluorouracil (5-FU), adriamycin, cisplatin and docetaxel IC50 values in MCF-7 cells and their pulse-selected variants as determined by the acid
phosphatase assay
IC50 values (ngml
 1) MCF-7 MCF-7 CisPt MCF-7 Txt MCF-7 Adr
5-FU 336±87 234±15 0.7 270±27 0.8 579±100 1.4
Adriamycin 43.1±2.7 47.0±9.5 1.1 58.0±5.9 1.3 110±14 2.6*
Cisplatin 580±120 1243±729 2.1 489±219 0.8 275±25 0.5*
Docetaxel 1.1±0.2 2.1±0.3 1.8 3.1±0.7 2.8* 10.5±3.6 4.8
Results are expressed as mean ±s.d. and represent the average of four independent experiments. Fold resistance of each variant is shown in bold and represents the IC50 value
of the variants divided by the IC50 value of the parental cells for each particular drug tested. *Indicates significance (Pp0.05).
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Figure 1 Expression of CYP1B1mRNA in MCF-7 cells and their resistant
variants by RT–PCR. HL60 cells treated with TCDD were used as positive
control. Ultrahigh purity (UHP) water was used as negative control.
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senzyme in all cell lines tested in response to TCDD treatment
(Figure 3B). This result indicates that TCDD is able to induce
CYP1B1 mRNA expression via the AhR in the panel of breast cell
lines, independently of ER status.
CYP1B1 siRNA transfection in MCF-7 Txt cells
CYP1B1 is upregulated in MCF-7 Txt cells, which show an
approximate three-fold increase in docetaxel resistance. To
investigate whether CYP1B1 expression could influence docetaxel
resistance in these cells, siRNA transfections were carried out to
knock down the expression of this gene. Three predesigned
siRNAs were used for CYP1B1; cells were transfected and then
exposed to different concentrations of docetaxel.
As seen in Figure 4, transfection of CYP1B1 siRNAs 1, 2 and 3
did not result in appreciable enhancement of docetaxel toxicity.
Remarkably, all three CYP1B1 siRNAs significantly decreased cell
survival in the absence of drug (Po0.05), suggesting that the
knockdown of this enzyme is detrimental to the viability of MCF-7
Txt cells.
CYP1B1 metabolism and drug toxicity
To study the degree to which CYP1B1 activity affects the toxicity of
anticancer drugs, in vitro toxicity assays were performed on A549
cells; these cells display no measurable EROD activity (data not
shown). A549 cells were exposed to different concentrations of
docetaxel, paclitaxel and 5-fluorouracil, which had been preincu-
bated with microsomes containing either human CYP1B1 and
cytochrome P450 NADPH reductase (P450R) or P450R cDNA
alone. Independent experiments were carried out, in which the
drug was incubated with microsomes for either 30min or 1h.
Figures 5A and B show that preincubation with CYP1B1 does not
affect the toxicity of any of the drugs tested on A549 cells, at any of
the two time points analysed.
DISCUSSION
The development of chemotherapy resistance in breast cancer is
considered to be multifactorial, involving several different
mechanisms (O’Driscoll and Clynes, 2006). These include multi-
drug efflux pumps such as MDR1, MRP1 and BCRP, but also
changes in expression of target proteins and growth factor
receptors. Resistance is also developed against antihormonal
treatment and aromatase inhibitors, highlighting the importance
of hormones in tumour homeostasis (Ring and Dowsett, 2004;
Dowsett et al, 2005; Weinberg et al, 2005).
Cytochrome P450 1B1 (CYP1B1) has been associated with the
malignant phenotype after a number of studies found the
expression of this P450 to be upregulated in malignant as
compared to normal tissue. Further investigations revealed that
CYP1B1 transfection increased docetaxel resistance in V79 cells
(McFadyen et al, 2001). However, no CYP1B1-generated docetaxel
metabolite has been detected to date, even after incubation of this
drug with recombinant CYP1B1 in a number of different
conditions (Bournique and Lemarie, 2002). The link between
CYP1B1 expression and docetaxel resistance therefore remains
unexplained.
It is a common feature of cytochromes P450 that the expression
of a particular enzyme is induced by its substrate. To find out
whether CYP1B1 expression could be induced by docetaxel,
expression of this enzyme was analysed in MCF-7 cells and also
in their resistant variants developed in our laboratory by pulse
selection with cisplatin, adriamycin and docetaxel. These cells
Table 2 EROD activity of MCF-7 cells
EROD activity
(picomoles resorufin per mg total protein per min)
MCF-7 ND
MCF-7 Txt 0.011±0.001
EROD¼ethoxyresorufin-O-deethylase; ND¼not detectable. After addition of 7-
ethoxy resorufin, cells were incubated at 371C for 40min. Samples were removed
and spun down, and the amount of resorufin present in the supernatant determined
by fluorescence (530nm excitation; 590nm emission). Results represent the average
of five independent experiments. Activity is expressed as picomoles resorufin per mg
of total protein per min.
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Figure 2 Expression of CYP1B1 mRNA in a panel of cell lines pulse
selected with docetaxel and their respective parent cells by RT–PCR.
HL60 cells treated with TCDD were used as positive control. Ultrahigh
purity (UHP) water was used as negative control.
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Figure 3 (A) Expression of CYP1B1 by RT–PCR in a panel of breast
cell lines after docetaxel treatment. Cells were exposed to 80ngml
 1
docetaxel or medium for 4h before mRNA extraction. (B) Expression of
CYP1B1 by RT–PCR in a panel of breast cell lines after TCDD treatment.
Cells were treated with 3.22ngml
 1 TCDD or vehicle (toluene) for 4h
before mRNA extraction.
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sdeveloped resistance to the drugs they were pulsed with: MCF-7
Txt cells showed an approximate three-fold increase in resistance
to docetaxel as compared to parent MCF-7 cells. CYP1B1 mRNA
levels were noticeably increased in MCF-7 Txt cells as compared to
parent and adriamycin-selected cells. Ethoxyresorufin-O-deethy-
lase activity levels, undetectable in MCF-7 parent cells, were low
but readily measurable in MCF-7 Txt cells.
To find out whether pulse selection with docetaxel had a general
effect on CYP1B1 expression, a panel of docetaxel-selected cell
lines – colon carcinoma Caco2, pancreatic carcinoma BxPc-3 and
squamous cell lung carcinoma SK-MES-1 – and their parental
counterparts were subjected to RT–PCR analysis. CYP1B1 mRNA
expression was undetectable in Caco2, BxPc-3 or SK-MES-1 parent
or pulse-selected cells, suggesting that the effect of docetaxel on
CYP1B1 expression is tissue-specific.
The effect of docetaxel on CYP1B1 mRNA expression was
further analysed in a panel of breast cell lines, ER-positive MCF-7
and MDA 453 cells and ER-negative BT-20 and MDA 231 cells.
Reverse transcription polymerase chain reaction results showed
that a short docetaxel treatment induced a modest increase in the
expression of CYP1B1 mRNA in MDA 453 and BT-20 cells,
suggesting that this effect is not dependent on ER status; only a
slight increase in CYP1B1 mRNA expression was observed in MDA
231 cells. Curiously, the effect was not observed in MCF-7 cells. It
should be noted that changes in expression were evaluated in MCF-7
cells after a short-term docetaxel treatment, while MCF-7 Txt cells
have been exposed to this drug on a regular basis and for a much
longer period of time. These cells also display changes in their
resistance profile, so in this case the induction of CYP1B1 mRNA
expression could be associated with the observed increase in
resistance.
CYP1B1 expression is regulated through the AhR pathway. To
confirm the functionality of this pathway, the panel of breast cell
lines was also exposed to the classic AhR agonist TCDD for 4h.
Induction of CYP1B1 mRNA was observed in all cell lines
irrespective of ER status, suggesting that disruption of the AhR
pathway is not a cause of the observed lack of acute CYP1B1 mRNA
induction by short-term docetaxel treatment in MCF-7 cells.
Transfection of three different CYP1B1 siRNAs directed to three
different sites in the CYP1B1 mRNA molecule resulted in
decreased cell survival in basal conditions (i.e., in the absence of
drug). This suggests that reduced CYP1B1 mRNA levels are
detrimental to cells. The effect was not dramatic, but it was
appreciable and indeed significant. In contrast, no major effect on
docetaxel toxicity was detected in CYP1B1 siRNA-transfected
MCF-7 Txt cells.
Our results with the siRNA experiments were quite unexpected.
It is known that CYP1B1 generates toxic metabolites from
oestrogen breakdown (Liehr, 2000); downregulation of CYP1B1
expression and consequent reduction in these toxic metabolites
would then be expected to result in increased survival. However,
we have found the opposite effect in MCF-7 Txt cells. It has
been shown that 4-hydroxy oestrogen, the main CYP1B1 oestrogen
metabolite, promotes MCF-7 cell proliferation (Schutze et al, 1993);
a decrease in the levels of this metabolite following CYP1B1
downregulation could explain the reduction in cell number
observed after CYP1B1 siRNA transfection. Although our
results show that CYP1B1 expression levels can affect cell
survival, the precise mechanism for this effect is not clear and
further experiments need to be performed. To study the
contribution of genotoxic oestrogen metabolites, we plan to carry
out CYP1B1 siRNA transfections in an oestrogen-depleted
environment using charcoal-stripped FCS and phenol red-free
medium. It would also be worthy to further analyse the
contribution of oestrogen to docetaxel-induced CYP1B1 expression,
due to the presence of an oestrogen-responsive element in the gene
promoter (Tsuchiya et al, 2004). Finally, it would be interesting to
analyse the effect of docetaxel on CYP1B1 expression in other cell
lines from hormone-dependent tissues, such as ovary and
endometrium.
The microsomal fractions of insect cells expressing recombinant
human cytochrome P450 cDNAs are a useful tool for the study of
P450-mediated drug metabolism, since they display significant
levels of enzymatic activity. Preincubation of 5-fluorouracil,
paclitaxel or docetaxel with CYP1B1-containing microsomes did
not affect the toxicity induced by these drugs in A549 cells,
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with CYP1B1 does not reduce their toxic effects.
Our results suggest that CYP1B1 does not mediate the direct
inactivation of docetaxel and that other factors are responsible for
the observed increase in docetaxel resistance in CYP1B1-trans-
fected cells. It is possible that the increased levels of CYP1B1
reported in tumour as compared to normal tissue are simply due
to the fact that the expression of this enzyme is associated with
carcinogenesis and/or with the resistant phenotype, rather than
being directly involved in drug resistance. However, knockdown of
CYP1B1 expression appears to be detrimental to some cells; this
suggests that CYP1B1 is not a simple resistance-associated marker
but an enzyme with a role in promotion of survival. CYP1B1 does
not appear to enhance docetaxel resistance by drug inactivation, so
the effect is likely to be exerted through an indirect mechanism. It
could be speculated that an endogenous metabolite of this enzyme
is responsible for the promotion of cell survival, but further studies
are needed to clarify this.
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